Mark C. Schneyer - 17 Nov 2025 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role: EVP, CHIEF FINANCIAL OFFICER
Signature: /s/ Jennifer J. Rhodes, Attorney-in-Fact
Issuer symbol: ACAD
Transactions as of: 17 Nov 2025
Transactions value $: -$243,114
Form type: 4
Filing time: 19 Nov 2025, 18:00:07 UTC
Previous filing: 16 Sep 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO	/s/ Jennifer J. Rhodes, Attorney-in-Fact	19 Nov 2025	0001899977

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACAD	Common Stock	Options Exercise		+9.91K	+22.65%		53.7K	17 Nov 2025	Direct	F1, F2
transaction	ACAD	Common Stock	Options Exercise		+9.91K	+18.46%		63.6K	17 Nov 2025	Direct	F1
transaction	ACAD	Common Stock	Sale	-$243K	-10.3K	-16.14%	$23.69	53.3K	18 Nov 2025	Direct	F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACAD	Restricted Stock Units	Options Exercise	$0	-9.91K	-100%	$0.00	0	17 Nov 2025	Common Stock	9.91K		Direct	F1, F5
transaction	ACAD	Restricted Stock Units	Options Exercise	$0	-9.91K	-100%	$0.00	0	17 Nov 2025	Common Stock	9.91K		Direct	F1, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2	Includes 327 shares of the Issuer's common stock acquired by the reporting person on November 14, 2025 pursuant to an employee stock purchase plan.
F3	The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
F4	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.69 to $23.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5	The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.
F6	The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.